KSI-101 is a first-in-class, high-strength intravitreal biologic designed to target IL-6 mediated inflammation and VEGF-mediated vascular permeability simultaneously 2 KSI-101: high formulation strength (100 mg/mL)
APEX Study Phase 1b Results on KSI-101 for Macular Edema Page 1 Page 3